Market News

As Pembina Pipeline (PBA) Shares Declined, Ronna Sue Cohen Upped Stake; Alyeska Investment Group LP Has Increased Its Oxford Immunotec Global Plc (OXFD) Position by $589,862; Valuation Declined

Oxford Immunotec Global PLC (NASDAQ:OXFD) Logo

Ronna Sue Cohen increased its stake in Pembina Pipeline Corp (PBA) by 36.95% based on its latest 2017Q4 regulatory filing with the SEC. Ronna Sue Cohen bought 28,385 shares as the company’s stock declined 12.97% with the market. The institutional investor held 105,204 shares of the oil & gas production company at the end of 2017Q4, valued at $3.81 million, up from 76,819 at the end of the previous reported quarter. Ronna Sue Cohen who had been investing in Pembina Pipeline Corp for a number of months, seems to be bullish on the $15.94 billion market cap company. The stock decreased 2.23% or $0.72 during the last trading session, reaching $31.46. About 574,314 shares traded. Pembina Pipeline Corporation (NYSE:PBA) has declined 3.38% since April 25, 2017 and is downtrending. It has underperformed by 14.93% the S&P500.

Anand Parekh increased its stake in Oxford Immunotec Global Plc (OXFD) by 3.35% based on its latest 2017Q4 regulatory filing with the SEC. Alyeska Investment Group Lp bought 45,374 shares as the company’s stock declined 10.21% with the market. The hedge fund run by Anand Parekh held 1.40M shares of the in vitro & in vivo diagnostic substances company at the end of 2017Q4, valued at $19.57 million, up from 1.36M at the end of the previous reported quarter. Alyeska Investment Group Lp who had been investing in Oxford Immunotec Global Plc for a number of months, seems to be bullish on the $317.45 million market cap company. The stock decreased 0.32% or $0.04 during the last trading session, reaching $12.27. About 46,145 shares traded. Oxford Immunotec Global PLC (NASDAQ:OXFD) has declined 19.42% since April 25, 2017 and is downtrending. It has underperformed by 30.97% the S&P500.

Among 4 analysts covering Oxford Immunotec (NASDAQ:OXFD), 4 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Oxford Immunotec had 10 analyst reports since July 19, 2017 according to SRatingsIntel. The firm has “Buy” rating by Cowen & Co given on Wednesday, September 27. On Thursday, September 28 the stock rating was initiated by BTIG Research with “Buy”. The stock has “Buy” rating by Cowen & Co on Wednesday, July 19. As per Tuesday, October 31, the company rating was maintained by Cowen & Co. The stock of Oxford Immunotec Global PLC (NASDAQ:OXFD) earned “Buy” rating by Robert W. Baird on Thursday, October 19. The firm has “Buy” rating given on Wednesday, August 16 by Cowen & Co. Piper Jaffray maintained the stock with “Buy” rating in Monday, January 8 report. The firm earned “Buy” rating on Tuesday, October 31 by Robert W. Baird. The firm has “Buy” rating given on Monday, January 22 by Cowen & Co.

Alyeska Investment Group Lp, which manages about $3.14 billion and $11.65 billion US Long portfolio, decreased its stake in J Jill Inc by 50,000 shares to 682,199 shares, valued at $5.32 million in 2017Q4, according to the filing. It also reduced its holding in Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) by 100,000 shares in the quarter, leaving it with 581,517 shares, and cut its stake in Argenx Se.

Investors sentiment increased to 1.57 in 2017 Q4. Its up 0.44, from 1.13 in 2017Q3. It increased, as 11 investors sold OXFD shares while 17 reduced holdings. 13 funds opened positions while 31 raised stakes. 23.93 million shares or 6.29% more from 22.51 million shares in 2017Q3 were reported. Consonance Capital Management Ltd Partnership holds 1.41% of its portfolio in Oxford Immunotec Global PLC (NASDAQ:OXFD) for 1.12M shares. Birchview Capital Limited Partnership has 1.04% invested in Oxford Immunotec Global PLC (NASDAQ:OXFD). Ny State Common Retirement Fund has 52,781 shares for 0% of their portfolio. First Light Asset Management Ltd invested 2.29% in Oxford Immunotec Global PLC (NASDAQ:OXFD). Stanley owns 49,514 shares or 0.15% of their US portfolio. Moreover, Point72 Asia (Hong Kong) Ltd has 0% invested in Oxford Immunotec Global PLC (NASDAQ:OXFD) for 367 shares. Tiaa Cref Investment Management Ltd reported 85,422 shares. Bnp Paribas Arbitrage holds 0% of its portfolio in Oxford Immunotec Global PLC (NASDAQ:OXFD) for 5,709 shares. Moreover, Penn Capital Mngmt has 0.21% invested in Oxford Immunotec Global PLC (NASDAQ:OXFD) for 212,868 shares. Parallax Volatility Advisers Limited Partnership has invested 0% in Oxford Immunotec Global PLC (NASDAQ:OXFD). Voya Management Ltd owns 12,003 shares. Northern Trust Corporation holds 267,709 shares. Alyeska Investment Gp Ltd Partnership reported 1.40 million shares. Spark Inv Mngmt Limited Liability accumulated 0.03% or 38,200 shares. Wasatch Advsr Incorporated stated it has 565,932 shares.

Since February 15, 2018, it had 0 buys, and 1 insider sale for $36,038 activity.

Oxford Immunotec Global PLC (NASDAQ:OXFD) Ratings Chart

Leave a Reply

Your email address will not be published. Required fields are marked *